374 related articles for article (PubMed ID: 30061035)
1. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
2. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
3. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
4. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
7. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
10. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
Lakomy R; Poprach A; Bortlicek Z; Melichar B; Chloupkova R; Vyzula R; Zemanova M; Kopeckova K; Svoboda M; Slaby O; Kiss I; Studentova H; Juracek J; Fiala O; Kopecky J; Finek J; Dusek L; Hejduk K; Buchler T
BMC Cancer; 2017 Dec; 17(1):880. PubMed ID: 29268716
[TBL] [Abstract][Full Text] [Related]
11. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
12. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
[TBL] [Abstract][Full Text] [Related]
13. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
14. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
[TBL] [Abstract][Full Text] [Related]
15. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials.
Sella A; Wang K; Sella T
Clin Genitourin Cancer; 2016 Oct; 14(5):415-419. PubMed ID: 27105724
[TBL] [Abstract][Full Text] [Related]
16. Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Voog E; Campillo-Gimenez B; Elkouri C; Priou F; Rolland F; Laguerre B; Elhannani C; Merrer J; Pfister C; Sevin E; L'Haridon T; Hasbini A; Moise L; Le Rol A; Malhaire JP; Delva R; Vauléon E; Cojocarasu O; Deguiral P; Cumin I; Cheneau C; Schlürmann F; Delecroix V; Boughalem E; Mollon D; Ligeza-Poisson C; Abadie-Lacourtoisie S; Monpetit E; Chatellier T; Desclos H; Coquan E; Joly F; Tessereau JY; Dupuy S; Déniel Lagadec D; Marhuenda F; Grudé F
Int J Cancer; 2020 Mar; 146(6):1643-1651. PubMed ID: 31318983
[TBL] [Abstract][Full Text] [Related]
17. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
20. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
